European Journal of Vascular & Endovascular Surgery
Volume 34, Issue 3 , Pages 314-321 , September 2007

Medical Therapy for Intermittent Claudication

  • T.E. Rowlands

      Affiliations

    • Department of Surgery, Derby Hospitals NHS Foundation Trust University of Nottingham, UK
    • ,
  • R. Donnelly

      Affiliations

    • School of Medical & Surgical Sciences, Centre for Integrated Systems Biology & Medicine, University of Nottingham, UK
    • Corresponding Author InformationCorresponding author. Prof. R. Donnelly, University of Nottingham Medical School, Derby City General Hospital, Uttoxeter Road, Derby DE22 3DT, UK.

,Accepted 1 April 2007.

References 

  1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621
  2. Fowkes FG, Housley E, Cawood EH. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–392
  3. Kannel WB, McGee DL. Update on some epidemiological features of intermittent claudication: the Framingham study. J Am Geriatr Soc. 1985;33:13–18
  4. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral artery disease, and atherothrombotic brain infarction in men and women ≥ 62 years of age. Am J Cardiol. 1994;74:64–65
  5. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119–128
  6. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547–553
  7. Donnelly R, Yeung J. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg. 2002;23:100–107
  8. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials 1965–1985. Br J Clin Pharmacol. 1988;26:569–576
  9. Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: a meta-analysis. J Cardiovasc Pharmacol. 1990;16(Suppl. 3):S81–S86
  10. Scottish Intercollegiate Guidelines Network (SIGN) . Diagnosis and management for Peripheral Arterial Disease. Edinburgh: Royal College of Physicians; October 2006;
  11. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114:84–91
  12. Horsch S, Walther C. Gingko biloba special extract Egb 761 in the treatment of peripheral arterial occlusive disease (PAOD) – a review based on randomized, controlled studies. Int J Clin Pharmacol Ther. 2004;42:63–72
  13. Pittler MH, Ernst E. Gingko biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276–281
  14. Jepson RG, Kleijnen J, Leng GC. Garlic for peripheral arterial occlusive disease. Cochrane Database Syst Rev. 1997;2:CD000095
  15. Price JF, Leng GC. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database Syst Rev. 2001;3:CD000188
  16. Brevetti G, Diehm C, Lambert D. European multicentre study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618–1624
  17. Villaruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2002;4:CD002785
  18. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041–2050
  19. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–530
  20. Dawson DL, Cutler BS, Meissner MH, Strandness DEJ. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicentre, randomized, prospective double-blind trial. Circulation. 1998;98:678–686
  21. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267–274
  22. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomised, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314–1319
  23. Hiatt WR. The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl. 2006;6:21–31
  24. Chapman T, Goa KL. Cilostazol. A review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3:117–138
  25. Strandness DE, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovasc Surg. 2002;36:83–91
  26. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942–1947
  27. Hittel N, Donnelly R. Treating peripheral arterial disease in patients with diabetes. Diabetes Obes Metab. 2002;4(Suppl. 2):S26–S31
  28. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475
  29. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001;87(Suppl.):28D–33D
  30. Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337–345
  31. Jonason T, Bergstron R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253–260
  32. Aronow WS, Nayak D, Woodworth S, Ahn C. Effects of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711–712
  33. Mohler ER, Hiatt WR, Creager MA. for the study investigators. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481
  34. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower extremity peripheral arterial disease. Circulation. 2003;107:757–761
  35. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolaemic patients with peripheral vascular disease. Am J Med. 2003;114:359–364
  36. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian Simvastatin Survival (4S). Study Am J Cardiol. 1998;81:333–335
  37. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo-controlled trial of atenolol and nifedipine and their combination. Br Med J. 1991;303:1100–1104
  38. Novo S, Abrignani MG, Pavone G, Zamueli M, Pernice C, Geraci AM, et al. Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. Int Angiol. 1996;15:169–174
  39. Lehoux S, Levy BI. Collateral artery growth: making the most of what you have. Circ Res. 2006;99:567–569
  40. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674
  41. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological neovascularization. Circ Res. 1999;85:221–228
  42. Buschmann I, Heil M, Jost M, Schaper W. Influence of inflammatory cytokines on arteriogenesis. Microcirculation. 2003;10:371–379
  43. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103:1231–1236
  44. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–563
  45. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion and incorporation into vascular structures. Circulation. 2002;106:2781–2786
  46. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?. Eur J Vasc Endovasc Surg. 2004;28:9–23
  47. Isner JM, Pieczek A, Schainfeld R, Hakey L, Ashasra T, Rosenfield K. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF in patient with ischaemic limb. Lancet. 1996;348:370–374
  48. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Hermiller JB. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC study). Lancet. 2002;359:2053–2058
  49. Rajagopalan S, Mohler ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease. Circulation. 2003;108:1933–1938
  50. Rajagopalan S, Olin JW, Young S, Erikson M, Grossman PM, Mendelsohn FO, et al. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther. 2004;15:619–624
  51. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with critical limb ischaemia using autologous bone marrow cell transplantation. Lancet. 2002;360:427–435

PII: S1078-5884(07)00266-3

doi: 10.1016/j.ejvs.2007.04.001

European Journal of Vascular & Endovascular Surgery
Volume 34, Issue 3 , Pages 314-321 , September 2007

Article Tools

* Image Usage & Resolution